191 related articles for article (PubMed ID: 30876495)
1. Comparison of patient reported symptom burden on an enhanced recovery after surgery (ERAS) care pathway in patients with ovarian cancer undergoing primary vs. interval tumor reductive surgery.
Meyer LA; Shi Q; Lasala J; Iniesta MD; Lin HK; Nick AM; Williams L; Sun C; Wang XS; Lu KH; Ramirez PT
Gynecol Oncol; 2019 Mar; 152(3):501-508. PubMed ID: 30876495
[TBL] [Abstract][Full Text] [Related]
2. PROFAST: A randomised trial implementing enhanced recovery after surgery for highcomplexity advanced ovarian cancer surgery.
Sánchez-Iglesias JL; Carbonell-Socias M; Pérez-Benavente MA; Monreal Clua S; Manrique-Muñoz S; García Gorriz M; Burgos-Peláez R; Segurola Gurrutxaga H; Pamies Serrano M; Pilar Gutiérrez-Barceló MD; Serrano-Castro S; Balcells-Farré MT; Pérez-Barragán C; Scaillet-Houberechts A; Cossio-Gil Y; Gil-Moreno A
Eur J Cancer; 2020 Sep; 136():149-158. PubMed ID: 32688208
[TBL] [Abstract][Full Text] [Related]
3. A meta-analysis of morbidity and mortality in primary cytoreductive surgery compared to neoadjuvant chemotherapy in advanced ovarian malignancy.
Bartels HC; Rogers AC; McSharry V; McVey R; Walsh T; O'Brien D; Boyd WD; Brennan DJ
Gynecol Oncol; 2019 Sep; 154(3):622-630. PubMed ID: 31349996
[TBL] [Abstract][Full Text] [Related]
4. Effect of an Enhanced Recovery After Surgery Program on Opioid Use and Patient-Reported Outcomes.
Meyer LA; Lasala J; Iniesta MD; Nick AM; Munsell MF; Shi Q; Wang XS; Cain KE; Lu KH; Ramirez PT
Obstet Gynecol; 2018 Aug; 132(2):281-290. PubMed ID: 29995737
[TBL] [Abstract][Full Text] [Related]
5. The optimal time for surgery in women with serous ovarian cancer.
Stewart JM; Tone AA; Jiang H; Bernardini MQ; Ferguson S; Laframboise S; Murphy KJ; Rosen B; May T
Can J Surg; 2016 Aug; 59(4):223-32. PubMed ID: 27240134
[TBL] [Abstract][Full Text] [Related]
6. When Less Is More: Minimally Invasive Surgery Compared with Laparotomy for Interval Debulking After Neoadjuvant Chemotherapy in Women with Advanced Ovarian Cancer.
Brown J; Drury L; Crane EK; Anderson WE; Tait DL; Higgins RV; Naumann RW
J Minim Invasive Gynecol; 2019; 26(5):902-909. PubMed ID: 30240899
[TBL] [Abstract][Full Text] [Related]
7. BRCA1-associated and sporadic ovarian carcinomas: outcomes of primary cytoreductive surgery or neoadjuvant chemotherapy.
Gorodnova T; Sokolenko A; Ni V; Ivantsov A; Kotiv K; Petrik S; Amelina I; Berlev I; Imyanitov E
Int J Gynecol Cancer; 2019 May; 29(4):779-786. PubMed ID: 30839285
[TBL] [Abstract][Full Text] [Related]
8. Perioperative trajectory of patient reported symptoms: a pilot study in gynecologic oncology patients.
Meyer LA; Nick AM; Shi Q; Wang XS; Williams L; Brock T; Iniesta MD; Rangel K; Lu KH; Ramirez PT
Gynecol Oncol; 2015 Mar; 136(3):440-5. PubMed ID: 25647455
[TBL] [Abstract][Full Text] [Related]
9. Oncologic Concerns regarding Laparoscopic Cytoreductive Surgery in Patients with Advanced Ovarian Cancer Submitted to Neoadjuvant Chemotherapy.
Favero G; Macerox N; Pfiffer T; Köhler C; da Costa Miranda V; Estevez Diz Mdel P; Fukushima JT; Baracat EC; Carvalho JP
Oncology; 2015; 89(3):159-66. PubMed ID: 25968072
[TBL] [Abstract][Full Text] [Related]
10. Integrated prediction model of patient factors, resectability scores and surgical complexity to predict cytoreductive outcome and guide treatment plan in advanced ovarian cancer.
Piedimonte S; Bernardini MQ; Ding A; Laframboise S; Ferguson SE; Bouchard-Fortier G; Cybulska P; Avery L; May T; Hogen L
Gynecol Oncol; 2022 Sep; 166(3):453-459. PubMed ID: 35820987
[TBL] [Abstract][Full Text] [Related]
11. Cost effectiveness of neoadjuvant chemotherapy followed by interval cytoreductive surgery versus primary cytoreductive surgery for patients with advanced stage ovarian cancer during the initial treatment phase.
Tran AQ; Erim DO; Sullivan SA; Cole AL; Barber EL; Kim KH; Gehrig PA; Wheeler SB
Gynecol Oncol; 2018 Feb; 148(2):329-335. PubMed ID: 29273308
[TBL] [Abstract][Full Text] [Related]
12. International validation of Enhanced Recovery After Surgery Society guidelines on enhanced recovery for gynecologic surgery.
Wijk L; Udumyan R; Pache B; Altman AD; Williams LL; Elias KM; McGee J; Wells T; Gramlich L; Holcomb K; Achtari C; Ljungqvist O; Dowdy SC; Nelson G
Am J Obstet Gynecol; 2019 Sep; 221(3):237.e1-237.e11. PubMed ID: 31051119
[TBL] [Abstract][Full Text] [Related]
13. Patients triaged to neoadjuvant chemotherapy have higher rates of sarcopenia: An opportunity for prehabilitation.
Fadadu PP; Polen-De CL; McGree ME; Weaver AL; Moynagh MR; Takahashi N; Langstraat CL; Cliby WA; Kumar A
Gynecol Oncol; 2021 Jan; 160(1):40-44. PubMed ID: 33109391
[TBL] [Abstract][Full Text] [Related]
14. A prospective study evaluating the impact of implementing the ERAS protocol on patients undergoing surgery for advanced ovarian cancer.
Agarwal R; Rajanbabu A; P V N; Goel G; Madhusudanan L; U G U
Int J Gynecol Cancer; 2019 Mar; 29(3):605-612. PubMed ID: 30833445
[TBL] [Abstract][Full Text] [Related]
15. Factors associated with delivery of neoadjuvant chemotherapy in women with advanced stage ovarian cancer.
Hinchcliff E; Melamed A; Bregar A; Diver E; Clemmer J; Del Carmen M; Schorge JO; Alejandro Rauh-Hain J
Gynecol Oncol; 2018 Jan; 148(1):168-173. PubMed ID: 29128105
[TBL] [Abstract][Full Text] [Related]
16. Treatment outcomes and predictive factors in patients ≥70 years old with advanced ovarian cancer.
Piedimonte S; Bernardini MQ; May T; Cybulska P; Ferguson SE; Laframboise S; Bouchard-Fortier G; Avery L; Hogen L
J Surg Oncol; 2022 Mar; 125(4):736-746. PubMed ID: 34786711
[TBL] [Abstract][Full Text] [Related]
17. Comparison of morbidity and survival between primary and interval cytoreductive surgery in patients after modified posterior pelvic exenteration for advanced ovarian cancer.
Revaux A; Rouzier R; Ballester M; Selle F; Daraï E; Chéreau E
Int J Gynecol Cancer; 2012 Oct; 22(8):1349-54. PubMed ID: 22954783
[TBL] [Abstract][Full Text] [Related]
18. Modeling treatment outcomes for patients with advanced ovarian cancer: Projected benefits of a test to optimize treatment selection.
Weaver DT; Raphel TJ; Melamed A; Rauh-Hain JA; Schorge JO; Knudsen AB; Pandharipande PV
Gynecol Oncol; 2018 May; 149(2):256-262. PubMed ID: 29486993
[TBL] [Abstract][Full Text] [Related]
19. Impact of prehabilitation during neoadjuvant chemotherapy and interval cytoreductive surgery on ovarian cancer patients: a pilot study.
Miralpeix E; Sole-Sedeno JM; Rodriguez-Cosmen C; Taus A; Muns MD; Fabregó B; Mancebo G
World J Surg Oncol; 2022 Feb; 20(1):46. PubMed ID: 35197061
[TBL] [Abstract][Full Text] [Related]
20. Intensive care admissions among ovarian cancer patients treated with primary debulking surgery and neoadjuvant chemotherapy-interval debulking surgery.
Pepin K; Bregar A; Davis M; Melamed A; Hinchcliff E; Gockley A; Horowitz N; Del Carmen MG
Gynecol Oncol; 2017 Dec; 147(3):612-616. PubMed ID: 28988028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]